Categories: world

Heated tobacco unit is said to be safer than cigarettes are not really, says studies – News – Akron Beacon Journal

The FDA is still considering, but the authors of the new studies have reached their own conclusion: IQOS should not…

The FDA is still considering, but the authors of the new studies have reached their own conclusion: IQOS should not be sold in the United States

In 30 countries around the world, consumers can slide a roll of dried tobacco into a smooth unit, heat it to 350 degrees and breathe in. The result is a hit of nicotine that feels like it comes from a traditional cigarette without producing any smoke.

Tobacco giant Philip Morris International wants to sell this device in the United States and is seeking approval because the IQOS system is less dangerous than old-fashioned smoking. However, an independent review of business data submitted to the Food and Drug Administration shows that IQOS resulted in no less harm than cigarettes on 23 of 24 actions. It can even cause some health problems like cigarettes, including liver disease.

The analysis was spearheaded by Big Tobacco foe Stanton Glantz, head of the University of California, San Francisco Center for Tobacco Control Research and Education. The results appear from eight paper published Tuesday by the BMJ magazine Tobacco Control.

The IQOS system has a cylinder where a leaf is drawn by dried tobacco product called “HeatStick” and warms to 350 degrees. But unlike a cigarette burning 600 degrees, a HeatStick never ignores.

Therefore, Philip Morris and its American partner Altria IQOS call a tobacco product with impaired harm. The FDA is now actively investigating whether this requirement can be made in the United States

In January, an FDA Advisory Panel agreed to switch entirely from cigarettes to IQOS significantly reducing the exposure of a smoker to harmful chemicals. However, the panel said that Philip Morris had not shown that the reduced exposure would likely result in a “measurable and substantial” reduction in disease and / or death.

The FDA is still considering, but the authors of the new studies have reached their own conclusion: IQOS should not be sold in the United States

One of the eight studies challenges the reliability of the tobacco company’s claim that compared to continued smokers American smokers who switched to IQOS saw improvements in two dozen “biomarkers” organ functions that often stand as surrogates for overall health. Almost none of the comparisons between those who continued to smoke and those who switched to the statistical standard that protects against fluke outcomes, found the analysis.

On 23 out of 24 actions, the FDA presented by Philip Morris “are differences within what would be expected based on simple randomness,” wrote Glantz. Instead of applying common statistical conventions and discussing them in submitting to the FDA &#821

1; a standard Glantz called “routine for such scientific analysis” – Philip Morris document “just emphasizes the direction of change,” he wrote.

It is the kind of statistical alloy that no scientist would escape with, he added: “No tobacco company would tolerate such claims made by the FDA or other public health authorities.”

Another of the published Tuesdays found that in cigarette smokers switching to IQOS, there was no evidence of decreased lung inflammation or improvements in lung function.

In the event of cancellation of reduced pneumonia for those who use their IQOS product, Philip Morris refers to the FDA for improvements in two biological measures – C-reactive protein and number of white blood cells – among smokers switching to IQOS. A team from UCSF claimed that while these measures are good indicators of systemic inflammation in humans, they are a bad measure of lung function or inflammation in the vital organs. And the team’s analysis indicates that changes in these measures are also not very robust.

It did not prevent Philip Morris from “Smokers Switching to (IQOS) would be at lower risk of chronic obstructive pulmonary disease compared to continued smoking,” noted the research team led by Dr. Farzad Moazed, a specialist on lung diseases and critics.

The Tobacco giant “not only correctly analyzes pneumonia in their human studies,” wrote the researchers, but it was also misleading concludes that their IQOS product reduces inflammation and the risk of COPD in humans, a statement simply unsupported by their data. “

Another study offered a warning about nausea effects not yet known.

Tobacco smoke contains over 7,000 separate chemical substances, many of which can cause disease, including cancer. The FDA has identified 93 harmful or potentially harmful components such as It wants manufacturers of tobacco products to measure emissions from their products.

Philip Morris identified emission comparisons of 58 products, including 40 recognized as harmful or potentially harmful by the FDA. In all of these constituents, IQOS emissions found lower than standard cigarette smoke .

However, the chemical company’s chemical analyzes also found that IQOS produced levels of 56 other constituents in higher concentrations than in cigarette smoke. For seven components, HeatSticks released levels at least 10 times higher than those found in cigarette smoke.

These ingredients included not in the FDA’s list of harmful or potentially harmful prayers constituents. However, the effect of these substances is “unknown”, the researchers wrote. “Because the ingredients in HeatSticks can differ from combustible cigarettes, including flavors and additives, the IQOS aerosol is likely to contain substances that are not in tobacco smoke.”

“Although some effects of IQOS may be lower than cigarettes, others may be as bad or worse,” Glantz said in summary of the new research. “The evidence does not support Phillip Morris International’s broad claims of reduced harm.” [19659003] Researchers noted that “heated” tobacco products in different forms have been designated as safer alternatives to cigarettes since the 1960s, and that tobacco companies have seen them as a means of circumventing rising regulation worldwide.

The FDA would have required that Philip Morris would assess the appeal of added flavors, as well as the “high-tech look” of IQOS, on younger consumers, wrote a team led by Stanford researcher Karma McKelvey. Her team also challenged whether an important assumption by Phillip Morris that IQOS users should abandon their cigarette habits and switch all the way to heated tobacco _ is true.

Published by